Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2012

View Archived Issues

Studies assess GS-9620-induced INF-alpha response and antiviral effects

Soligenix reports thermostability of vaccines using ThermoVax

U.S. university patents new candidate vaccine adjuvants

Novel potential vaccines reported for enteroviral infections

Phase I trial studies vandetanib combination therapy for brain cancer

Scientists in Europe uncover new recognition factor for HIV-1 entry

Phase I data available on antisense drug for ALS

IntelGenx and Redhill Biopharma launch pivotal trial of antimigraine product

Epizyme forms strategic partnership with Celgene

Shire reports topline data on drug for binge eating disorder

Galenea to receive funds from the Stanley Medical Research Institute

Phase I trial tests once-daily and intermittent INK-128 dosing

Continuation recommended for trial assessing whipworm egg therapy for Crohn's disease

Mount Sinai School of Medicine evaluates IGF-1 product in autism subtype

Omthera Pharmaceuticals reports topline results from EVOLVE study

Advanced Cell Technology clear to continue Stargardt's macular dystrophy trials

GlaxoSmithKline files application in Japan for ofatumumab

Novartis extends oncology discovery research collaboration

Dynavax files BLA for hepatitis B vaccine

FDA revises Victrelis label

Jazz Pharmaceuticals enters acquisition agreement

Amgen gives update on Xgeva sBLA

Investigation at Bionature yields novel candidate oncolytics

Novel DUB/FAF-X inhibitors presented

InterMune designs novel HCV NS3/NS4A inhibitors

German university announces novel candidate analgesics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...